ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾
ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÐÂÎÅ
Group News
¡¾AACR 2025¡¿ÉÏÏ¸Ç°ÑØÍ»ÆÆÒ» | È«ÇòÊ×´´6Сʱ¼«ËÙÖÆ±¸£ºJL-ÉÁCAR-T?ÖúÁ¦¶ÌÖÜÆÚ¡¢µÍ±¾Ç®¡¢³¤Ò©Ð§ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ò©Î↑·¢
2025-05-15

4ÔÂ25ÈÕ-30ÈÕ£¬£¬£¬ £¬£¬ £¬±¸ÊܹØ×¢µÄÃÀ¹ú°©Ö¢Ñо¿Ð­»á£¨AACR£©Äê»áÔÚÃÀ¹úÖ¥¼Ó¸çÕÙ¿ª£¬£¬£¬ £¬£¬ £¬±¾½ì¾Û»áÒԓͳһ°©Ö¢¿ÆÑ§Óëҽѧ£ºÒ»Á¬Á¢Òì´øÀ´Àå¸ï”ΪÖ÷Ìâ¡£¡£¡£¡£¡£±ü³Ö“ÁÆÐ§ÎªºË£¬£¬£¬ £¬£¬ £¬ÀèÃñ¿É¼°”µÄÒ©Î↑·¢ÀíÄ£¬£¬ £¬£¬ £¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ò»Á¬Íƶ¯JL-ÉÁCAR-T™Îª½¹µãµÄÒªº¦ÊÖÒÕÆ½Ì¨¿ª·¢£¬£¬£¬ £¬£¬ £¬ÊµÏÖÔ­´´·Ç²¡¶¾ÔØÌå»ùÒòдÈëÊÖÒÕ¡¢ÄÉÃ׿¹ÌåVHHMAb®ÊÖÒյȵײãÊÖÒÕµÄÒ»Á¬Í»ÆÆ£¬£¬£¬ £¬£¬ £¬¼ÓËÙÁ¢ÒìÖÎÁÆÒ©Î↑·¢Àú³Ì¡£¡£¡£¡£¡£±¾´Î¾Û»á£¬£¬£¬ £¬£¬ £¬¼¯ÍʲÓÐ5Ïî×îÐÂÑо¿Ð§¹û»ñÑûÏÖ³¡Õ¹Ê¾£¬£¬£¬ £¬£¬ £¬ÁýÕÖ´Óµ×²ãÆ½Ì¨Í»ÆÆµ½ÓÅÊÆ¿¹Ìå·¢Ã÷£¬£¬£¬ £¬£¬ £¬ÔÙ¹âÁÙ´²Ó¦ÓÃת»¯µÄÍêÕûÒ©Î↑·¢ÏµÍ³¡£¡£¡£¡£¡£³ä·ÖÕ¹ÏÖÁ˼¯ÍÅÔÚË¢ÐÂCAR-TµÈÁ¢ÒìÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ò©Îï¿É¼°ÐÔºÍÖÎÓúÐÔ·½ÃæµÄǰհ½á¹¹¼°ÁÉÀ«Ô¶¾°¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

BZE2204ΪһÏîȫеÄÎÞÐèÌåÍâ×÷ÓýµÄ³¬¿ìËٷDz¡¶¾ÔØÌåÈý°ÐµãѪҺÁöCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÏîÄ¿¡£¡£¡£¡£¡£ÓÉÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÍŽáÉϺ£´óѧÁ¥ÊôÃϳ¬Ö×ÁöÒ½Ôº¼°ÃÀ¹ú×Ó¹«Ë¾Chantibody£¨CHANTIBODY THERAPEUTICS INC.£©ÅäºÏ¿ªÕ¹¡£¡£¡£¡£¡£

 

BZE2204½ÓÄɼ¯ÍÅJL-ÉÁCAR-T™ÖƱ¸¹¤ÒÕÆ½Ì¨£¬£¬£¬ £¬£¬ £¬×î¶ÌÖÆ±¸¹¤ÒÕµÄʱ¼äΪ6Сʱ£¨6h£©Íê³É´Óµ¥²ÉѪµ½ÖƼÁµÄÈ«Àú³Ì£¬£¬£¬ £¬£¬ £¬×îºéÁ÷ƽ°ü¹ÜTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄ¸ÉÐÔºÍÀ©ÔöÄÜÁ¦£¬£¬£¬ £¬£¬ £¬ÔÚÁÙ´²Ç°¶¯ÎïÊý¾ÝºÍIITÁÙ´²ÊµÑéÉ϶¼Õ¹ÏÖ³öÁËÓÅÒìµÄ¿¹Ö×ÁöЧ¹û£¬£¬£¬ £¬£¬ £¬ÊÇÉÁCAR-TÖÆ±¸ÊÖÒÕÁ¢ÒìÓë¶à°ÐµãCARÉè¼ÆÁ¢ÒìµÄÓлúÍŽá¡£¡£¡£¡£¡£

 

BZE2204ÌåÄÚÀ©ÔöÄÜÁ¦Ç¿£¬£¬£¬ £¬£¬ £¬ÒÔͨÀýÊÐÊÛCAR-T¼ÁÁ¿µÄ1/40£¬£¬£¬ £¬£¬ £¬µÖ´ïͨÀý¼ÁÁ¿²úÆ·30-200±¶µÄ Cmax (CAR-T/ul)¡¢17-150±¶µÄAUC(CAR-T/ul*d)¡£¡£¡£¡£¡£ÏÖÔÚ6h¹¤ÒÕ¿ªÕ¹µÄIITÁÙ´²ÊµÑéÖУ¬£¬£¬ £¬£¬ £¬ÔÚÄÑÖθ´·¢ÃÖÂþ´óBÁܰÍÁö£¨r/r NHL£©Ä©Ïß3Àý»¼ÕßÖеִïÁÙ´²¿Í¹Û»º½âÂÊORR=100%£¬£¬£¬ £¬£¬ £¬ÍêÈ«»º½âÂÊ£¨CR£©½ü70%£¨×èÖ¹·¢¸åʱÒѸüÐÂÖÁCR=100%£©£¬£¬£¬ £¬£¬ £¬ÇÒ¶¾¸±×÷Óü«Ð¡£¬£¬£¬ £¬£¬ £¬ÎÞÈý¼¶»òÒÔÉÏCRS£¬£¬£¬ £¬£¬ £¬ÎÞDLT¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»¼Õß»ØÊäºó»Ö¸´ºÃ£¬£¬£¬ £¬£¬ £¬Ò»Á¬»º½â±ÈÀý¸ß¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ÕªÒªºÅ£º3173

 

ÕªÒªÎÊÌ⣺

JL-Lightning CAR-T£¬£¬£¬ £¬£¬ £¬a Next Generation Non-viral CAR-T without In-Vitro Culturing Procedure, Shows High Clinical Efficacy, Good Safety with Low Dosage

 

ÕªÒªÄÚÈÝ£º

BZE2204ÊÇÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾´îÔØJL-ÉÁCAR-T™ÊÖÒÕÆ½Ì¨µÄÈý°ÐµãѪҺÖ×ÁöCAR-T²úÆ·£¬£¬£¬ £¬£¬ £¬²úÆ·ÓÉanti-CD19, CD22 ºÍ BCMA Èý¸öVHH×é³É£¬£¬£¬ £¬£¬ £¬ÒÔ4-1BB ºÍCD3ζ×÷Ϊ°ûÄڽṹÓò¡£¡£¡£¡£¡£´ËÉè¼ÆÀíÄ£¬£¬ £¬£¬ £¬ÊÇΪÁËʹ²úÆ·ÄÜÉî¶ÈɱÉ˸÷½×¶ÎµÄBÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬ £¬£¬ £¬µÖ´ï¼²²¡³¹µ×»º½âµÄЧ¹û¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬ £¬£¬ £¬¶àCARÉè¼ÆÄÜÓÐÓñÜÃâCD19ÒõÐÔµÄѪҺÖ×Áö¸´·¢£¬£¬£¬ £¬£¬ £¬ÑÓÉìÎÞÏ£ÍûÉúÑÄÆÚ£¨PFS£©£¬£¬£¬ £¬£¬ £¬Ê¹»¼ÕßÓиü´óµÄ»ñÒæ¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬ £¬£¬ £¬ÏîÄ¿½ÓÄÉÓµÓÐ×ÔÖ÷֪ʶ²úȨµÄJLת×ùø¾ÙÐÐת×ù£¬£¬£¬ £¬£¬ £¬Ïà¶ÔÊÐÊÛÆäËûת×ù×ÓЧÂʸü¸ß£¬£¬£¬ £¬£¬ £¬¶¾ÐÔ¸üµÍ£¬£¬£¬ £¬£¬ £¬Çå¾²£¨ÎÞ²åÈëÆ«ºÃ£©¸ßЧ¡£¡£¡£¡£¡£×ÔÓÐ֪ʶ²úȨµÄ“Tini-Plasmid”ϵͳ£¨Ì«ÖÊÁ££© Ò²ÒòÆä¼«Ð¡µÄ¹Ç¼Ü´óС£¡£¡£¡£¡£¨~500bp£©ÖúÁ¦¸ßЧµÍ¶¾µÄ·Ç²¡¶¾CAR»ùÒòתȾ¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ BZE2204ÏîÄ¿µÄ·Ö×ÓÉè¼ÆÓëת×ùÊÖÒÕÆ½Ì¨

 

¹«Ë¾¶À´´µÄJL-Lightning™ÎÞ×÷Óý³¬¿ìËٷDz¡¶¾CAR-TÖÆ±¸Æ½Ì¨£¬£¬£¬ £¬£¬ £¬Ê¹ÓÃÉÏÊöµÄת×ùøºÍÌ«ÖÊÁ£ÏµÍ³£¬£¬£¬ £¬£¬ £¬½«ÊÐÊÛ²úÆ·¹Å°å¹¤ÒÕµÄ9-11ÌìÖÆ±¸Ê±¼äËõ¶Ìµ½30h£¨V-30h£©ºÍ6h£¨V-6h£©.ͨ¹ýËõ¶ÌÌåÍâ×÷Óýʱ¼ä£¬£¬£¬ £¬£¬ £¬ÔÚ°ü¹Ü»îÂÊ¡¢×ªÈ¾Ð§ÂʺÍCAR-T¹¦Ð§µÄÌõ¼þÏ£¬£¬£¬ £¬£¬ £¬´ó·ùÌá¸ßCAR-T²úÆ·µÄ¸ÉÐÔ±íÐÍ£¨Tscm+Tcm£©£¬£¬£¬ £¬£¬ £¬ÌáÉýÌåÄÚÀ©ÔöDZÁ¦£¬£¬£¬ £¬£¬ £¬´Ó¶øÊ¹µÃÁÙ´²»ØÊäºóÄÜÔÚ¸üµÍµÄ¼ÁÁ¿Ï»ñµÃ¸ü¸ßµÄÒ©´ú¶¯Á¦Ñ§Êý¾ÝºÍ¸ü¼ÑµÄÁÙ´²ÁÆÐ§¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ JL-Lightning™ÎÞ×÷Óý³¬¿ìËٷDz¡¶¾CAR-TÖÆ±¸Æ½Ì¨

 

ÁÙ´²Ç°¶¯ÎïÊý¾ÝÏÔʾ£¬£¬£¬ £¬£¬ £¬BZE2204ÔÚ¼«µÍ¼ÁÁ¿Ï£¨1E5 CAR-T/mice£©¿ÉÒÔʹRajiÖ×ÁöÏûÍË£¨CD19+CD22+£©£¬£¬£¬ £¬£¬ £¬Ö×ÁöÏûÍË·ºÆð¼ÁÁ¿ÒÀÀµ¡£¡£¡£¡£¡£Ð¡ÊóµÄÉúÑÄÇúÏßչʾ²úÆ·ÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£¡£CAR-TÌåÄÚÀ©ÔöÊý¾ÝÒ²ÏÔʾ²úÆ·¼«¼ÑµÄÀ©ÔöЧÂÊ£¬£¬£¬ £¬£¬ £¬ÊǵͼÁÁ¿Ï¿ØÖÆÖ×ÁöÉú³¤µÄÖ÷ÒªÒòËØ¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²Ç°ÌåÄÚʵÑéÊý¾Ý£¨RajiÖ×ÁöÄ£×Ó£©

 

ÁÙ´²Ç°¶¯ÎïÊý¾ÝÏÔʾ£¬£¬£¬ £¬£¬ £¬BZE2204ÄܸßЧ¿ØÖÆBCMA+µÄMM1SÖ×ÁöÄ£×ÓÔÚСÊóÌåÄÚµÄÉú³¤¡£¡£¡£¡£¡£Êý¾Ý±ÈÕÕÁËÁ½ÖÖBCMAµ¥±í´ïµÄCAR-T£¨ÎÒ¹«Ë¾µÄBCMA-CAR-TºÍÊÐÊÛ¾ºÆ·BCMA CAR-T£©ºÍBZE2204Èý°ÐµãCAR-TµÄÖ×ÁöÒÖÖÆÐ§ÂÊ¡£¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬ £¬£¬ £¬BZE2204²úÆ·µÄÈý°ÐµãCAR-TÔÚÀ©ÔöºÍÖ×ÁöÒÖÖÆÐ§ÂÊÉÏÓÅÓÚµ¥BCMA CAR-T£¨BCMA-CAR·Ö×ÓÏàͬ£©£¬£¬£¬ £¬£¬ £¬Á½¿î²úÆ·ÓÅÓÚÊÐÊÛµÄBCMA-CAR-T²úÆ·¡£¡£¡£¡£¡£BZE2204²úÆ·¸üչʾÁËÓÅÒìµÄ·À¸´·¢Ð§¹û£¨d21¼°ÒԺ󣩣¬£¬£¬ £¬£¬ £¬Ïà¶Ôµ¥°ÐµãBCMA-CAR-T£¬£¬£¬ £¬£¬ £¬±¾²úÆ·Äܸü³¤Ê±¼äµÄÒÖÖÆÖ×Áö¸´·¢£¬£¬£¬ £¬£¬ £¬Ô¤Ê¾×ÅÁÙ´²¿ÉÄÜÓиü³¤µÄÎÞÏ£ÍûÉúÑÄÆÚ»ñÒæ¡£¡£¡£¡£¡£Ð¡ÊóµÄÉúÑÄÇúÏßͬʱչʾ²úÆ·ÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²Ç°ÌåÄÚʵÑéÊý¾Ý£¨MM1SÖ×ÁöÄ£×Ó£©

 

ÁÙ´²¼Æ»®Éè¼ÆÓëÖмÁÁ¿×飨5E4 CAR-T/kg£©ÔÚV-30ºÍV-6hÁ½¸ö¹¤ÒÕϵÄIITÁÙ´²Êý¾Ý¡£¡£¡£¡£¡£Êý¾ÝÏÔʾÖмÁÁ¿×é6Ãû»¼ÕßORR¾ùΪ100%£¬£¬£¬ £¬£¬ £¬CR%=67%£¨×èÖ¹·¢¸åʱ£¬£¬£¬ £¬£¬ £¬V-6hµÄÈýÃû»¼ÕßÒѸ濢ÍêÈ«»º½âÂÊ£¨CR£©=100%£©.V-30h¹¤ÒÕÖÐδ¸æ¿¢CRµÄ»¼ÕßÖ×Áö¸ººÉ¼«´ó£¨µ¥¸öÖ×Áö¸ººÉÁè¼Ý7000mm2£©£¬£¬£¬ £¬£¬ £¬¾­ÓÉÖÎÁÆÖ×ÁöÒѾ­ÏûÍËÁè¼Ý90%¡£¡£¡£¡£¡£²úÆ·Çå¾²ÐÔÓÅÒ죬£¬£¬ £¬£¬ £¬ËùÓл¼Õß¾ùÖ»ÓÐG1 CRS£¬£¬£¬ £¬£¬ £¬Ö»ÓÐÒ»Àý»¼Õß·ºÆðG3 ICANS²¢ÔÚÁÙ´²¸ÉÔ¤1ÌìÒԺ󻺽â¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²ÊµÑ鼯»®¼°Êý¾Ý»ã×Ü

 

ÁÙ´²Ò©´ú¶¯Á¦Ñ§Êý¾Ý£¨PK£©ÏÔʾBZE2204 CAR-T²úÆ·¼«¸ßµÄÌåÄÚÀ©ÔöÄÜÁ¦¡£¡£¡£¡£¡£ÓëÆäËûCAR-T¿ìËÙ¹¤ÒÕÀàËÆ£¬£¬£¬ £¬£¬ £¬BZE2204²úÆ·´ï·åʱ¼ä£¨Tmax£©Îªd14×óÓÒ£¬£¬£¬ £¬£¬ £¬µ«ÒÔµÍÓÚÊÐÊÛ²úÆ·1/40µÄ¼ÁÁ¿ÏµִïͨÀý¼ÁÁ¿²úÆ·30-200±¶µÄ Cmax (CAR-T/ul), ÒÔ¼°17-150±¶µÄAUC(CAR-T/ul*d)£¬£¬£¬ £¬£¬ £¬ÇÒ¶¾¸±×÷ÓÃС£¬£¬£¬ £¬£¬ £¬ÎÞ3¼¶»òÒÔÉϵÄCRS£¬£¬£¬ £¬£¬ £¬ÎÞDLT£¬£¬£¬ £¬£¬ £¬Õ¹Ê¾Á˲úÆ·¸ßЧµÍ¶¾µÄÀ©Ôöģʽ¡£¡£¡£¡£¡£

£¨ÊÐÊÛÊý¾Ý¾ùÀ´×Ô¹ûÕæ½ÒÏþµÄ²Î¿¼ÎÄÏ×£©

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²Ò©´ú¶¯Á¦Ñ§Êý¾Ý»ã×ܼ°ÓëÊÐÊÛ²úÆ·±ÈÕÕ

 

´ú±íÐÔ»¼ÕßÁÙ´²Êý¾ÝÏÔʾV-30hºÍV-6hµÄ»¼ÕߵĻùÏßÊý¾ÝºÍÔÚ½ÓÊÜBZE2204 JL-Lightning CAR-TÖÎÁƺóµÄËæ·ÃÆÚµÄPET-CTͼ¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»¼ÕßÔÚ½ÓÊÜBZE2204²úÆ·»ØÊäºó£¬£¬£¬ £¬£¬ £¬ÔÚ28ÌìÄÚ¼´µÖ´ïÖ×ÁöÍêÈ«»º½â(CR)£¬£¬£¬ £¬£¬ £¬²¢ÔÚºóËæ·ÃÆÚÖлñµÃÒ»Á¬»º½â¡£¡£¡£¡£¡£×èÖ¹ÏÖÔڸüÁÁ¿ÏÂV-30h»¼Õß×î³¤Ëæ·ÃÆÚΪ6¸öÔ£¬£¬£¬ £¬£¬ £¬V-6h×黼Õß×î³¤Ëæ·ÃÆÚΪ3¸öÔ£¬£¬£¬ £¬£¬ £¬ºóÐøÊý¾Ý½«Ò»Á¬¸üС£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ´ú±íÐÔ»¼ÕßÁÙ´²PET-CTÊý¾Ýչʾ£¨V-30hÓëV-6h£©

 

½áÂÛ£º

1. JL-Lighting CAR-T ÎÞ×÷Óý³¬¿ìËÙÆ½Ì¨¹¤ÒÕ´îÔØJLת×ùø¼°Ì«ÖÊÁ£ÏµÍ³£¬£¬£¬ £¬£¬ £¬Õ¹Ê¾Á˷Dz¡¶¾¹¤ÒÕϸßЧµÍ¶¾¡¢¸ß»îµÍ·Ö½âµÄÁìÏȵÄCAR-TÖÆ±¸¹¤ÒÕ¡£¡£¡£¡£¡£

2.ÁÙ´²Ç°Êý¾Ý֤ʵÎúBZE2204 CAR-T²úÆ·ÔÚСÊóÌåÄÚ¸ßÔöֵDZÁ¦¡¢¸ßÖ×ÁöÒÖÖÆÐ§Âʼ°¸ßÇå¾²ÐÔµÄÌØµã£¬£¬£¬ £¬£¬ £¬ÇкÏÁÙ´²Ç°ÆÀ¹ÀµÄÔ¤ÆÚ¡£¡£¡£¡£¡£

3. ÏÖÓÐÁÙ´²Êý¾ÝչʾBZE2204 ÓµÓм«¸ßµÄÒ©´ú¶¯Á¦Ñ§À©ÔöÄÜÁ¦£¨PK£©ºÍÔÚ¼«µÍ¼ÁÁ¿ÏÂÓÅÒìµÄÌåÄÚÁÆÐ§£¨ORR=100%£¬£¬£¬ £¬£¬ £¬CR>67%£©.ÁÙ´²ÊµÑ黹ÔÚ½øÒ»²½¿ªÕ¹ÖС£¡£¡£¡£¡£

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾
·µ»Ø¶¥²¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿